McKesson completes acquisition of Medical Specialties Distributors
McKesson announced on Friday that it has completed its previously announced acquisition of Medical Specialties Distributors, a distributor of infusion and medical-surgical supplies as well as biomedical services to alternate site and home health providers.
The deal, valued at $800 million, was initially announced in April as the San Francisco-based company unveiled a multi-year strategic growth initiative focused on creating new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure.
The acquisition of MSD supports two of the company’s strategic growth pillars — manufacturer services and specialty — and complements its existing low-cost site of care infusion platform. MSD’s established offering to providers in the home infusion market, as well as technology and services to support customers and patients using these products, will allow McKesson to provide incremental services to other customer segments, according to the company.
“This acquisition complements our alternate-site service platform and, in combination with strong organic performance, is expected to deliver revenue growth in the low double-digit range for fiscal 2019,” John Hammergren, McKesson chairman and chief executive officer, told analysts during the company’s fourth quarter conference call in May.
The deal, valued at $800 million, was initially announced in April as the San Francisco-based company unveiled a multi-year strategic growth initiative focused on creating new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure.
The acquisition of MSD supports two of the company’s strategic growth pillars — manufacturer services and specialty — and complements its existing low-cost site of care infusion platform. MSD’s established offering to providers in the home infusion market, as well as technology and services to support customers and patients using these products, will allow McKesson to provide incremental services to other customer segments, according to the company.
“This acquisition complements our alternate-site service platform and, in combination with strong organic performance, is expected to deliver revenue growth in the low double-digit range for fiscal 2019,” John Hammergren, McKesson chairman and chief executive officer, told analysts during the company’s fourth quarter conference call in May.